The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 17 Article 5
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 17, 24 April 2008
Surveillance and outbreak reports
A survey on cases of tick-borne encephalitis in European countries
  1. National Consultant Laboratory for Tick-borne encephalitis and further flaviviruses*

Citation style for this article: Donoso Mantke O, Schädler R, Niedrig M. A survey on cases of tick-borne encephalitis in European countries. Euro Surveill. 2008;13(17):pii=18848. Available online:
Date of submission: 05 December 2007

The European Network for Diagnostics of “Imported” Viral Diseases (ENIVD) is finalising a project to improve the diagnostic and monitoring of encephalitis viruses in Europe. Part of this study was to analyse the present surveillance situation for tick-borne encephalitis (TBE), which is the most important flavivirus infection of the central nervous system in the European Union (EU) and Russia. A questionnaire was mailed to contact points in all Member States of the EU and three non-EU countries (Norway, Russia and Switzerland) to summarise their TBE surveillance and prevention activities. Information was requested on case definition, type of laboratory tests for TBE diagnostics, investigations regarding tick-transmitted diseases, mapping of endemic foci, vaccination programmes, and recommendations for travellers. The survey gives an overview of the existing epidemiological and laboratory sources of information and the number of TBE cases from 2004 until 2007, but also showed that, in particular, case definitions, diagnostic assays for confirmation, and methods/indicators for mapping risk areas differ widely across the participating countries. The data will help to develop recommendations for the standardisation and quality control of TBE surveillance and diagnostics.


Tick-borne encephalitis (TBE) is the most important flavivirus infection of the central nervous system (CNS) in Europe and Russia. The total annual number of cases is estimated to be up to 10,000 in Russia and about 3,000 in European countries [1-4]. According to the International Committee for Taxonomy of Viruses, TBE virus is classified as one species with three subtypes, namely the European subtype (which comprises almost all known isolates from Europe), the Siberian subtype (mainly isolates from Urals, Siberia and far-eastern Russia) and the Far Eastern subtype (mainly isolates from far-eastern Russia, China and Japan).

The three TBE virus subtypes are associated with varying degrees of disease severity [2-4]. Human infections with Far Eastern subtype viruses are usually severe, frequently with encephalitic symptoms (focal meningoencephalitis or polyencephalitis), with an associated fatality rate between 5 and 35%. This type does not cause chronic disease. In contrast, TBE virus infections of the Siberian subtype cause a less severe disease (fatality rate between 1 and 3%), with a tendency for patients to develop chronic or extremely prolonged infections accompanied by diverse neurological and/or neuropsychiatric symptoms. In contrast to these two forms, infections caused by European strains typically take a biphasic course [5]: after a short incubation period (usually 7–14 days, with extremes of 4–28 days), the first (viraemic) phase presents as an uncharacteristic influenza-like illness lasting 2–4 days (range 1–8 days) with fever, malaise, headache, myalgia, gastrointestinal symptoms, leukocytopenia, thrombocytopenia and elevated liver enzymes, often followed by a symptom-free interval of about one week (range 1–33 days). The second phase of TBE occurs in 20–30% of infected patients and is marked by four clinical features of different severity (meningitis, meningoencephalitis, meningoencephalomyelitis or meningoencephalo-radiculitis) and the appearance of specific antibodies in the serum and cerebrospinal fluid (CSF). This is usually the time when patients with high fever and severe headache seek medical advice. The fatality rate in adult patients is less than 2%. However, severe courses of TBE infection with higher mortality and long-lasting sequelae often affecting the patient’s quality of life have been correlated with increased age [6-8]. More detailed information on the clinical picture, case definition and other issues of interest are available in a TBE fact sheet on the ENIVD website [].

The epidemiology of TBE is closely related to the ecology and biology of ticks [2,3,9,10]. In nature, TBE virus is propagated in a cycle involving permanently infected ticks and wild vertebrate hosts. Virus transmission occurs horizontally between tick vectors and vertebrates, especially between spring and autumn, with small mammals (mainly rodents) serving as virus reservoirs. In addition, trans-stadial and trans-ovarial transmission of the virus, as well as co-feeding of infected and non-infected ticks on the same host play a major role in virus transmission [11]. In contrast to other tick-transmitted diseases, such as Lyme borreliosis, TBE is distributed in an endemic pattern of so-called natural foci over a wide geographical area focussed on central Europe, the Baltic states and Russia. The distribution of TBE is determined by the occurrence of the respective tick vectors in certain regions [3,10]. While Ixodes ricinus is the prevalent hard tick species across Europe and therefore the most important transmitter of the European TBE virus subtype, Ixodes persulcatus occurs in forest regions of the Urals, Siberia and far-eastern Russia and is the main vector of the other subtypes. Co-circulation of two or all three subtypes could be shown for Finland and the Baltic states where the distribution areas of the two main tick species overlap [12,13].

However, the virus prevalence in ticks as well as the prevalence of infected ticks within the risk areas can vary [4,9,14,15]. Countries with high-risk areas are Russia, Latvia, Lithuania and Estonia. TBE is also a significant issue in Germany, the Czech Republic, Poland, Switzerland, Sweden, Finland, Slovakia, Hungary and Slovenia. Even in Austria, the only country with progressively decreasing incidences since 1981 (due to high vaccination coverage [16]), the occurrence of TBE may be of relevance for unvaccinated tourists. In France, Italy, Greece, Norway and Denmark, TBE is of minor importance. In the United Kingdom, Ireland, Belgium, the Netherlands, Luxembourg, Spain and Portugal, TBE is not indigenous. Detailed epidemiological statistics from 1990 onwards can be obtained from the website of the International Scientific Working Group on TBE [].

An increase of TBE incidence has been observed in the risk areas (both high- and low-risk) in some of the endemic countries mentioned above, especially in the last decade [15,17-20]. In addition, new TBE foci have appeared in Europe. This is due to a complex interrelation of several factors, such as social (e.g. socio-political changes, human leisure activities), ecological (e.g. effects of climate changes on vectors) and/or technological factors (e.g. advanced diagnostics and increased medical awareness) [20-24]. The collection of epidemiological data is indispensable in order to predict endemic foci and to recommend preventive measures. Several methods can be employed to investigate the epidemiological situation of TBE [10]:

examination of ticks and animal reservoirs for the presence of TBE virus (especially by molecular diagnostic techniques);

2) seroprevalence study of people exposed to ticks; and

3) describing clinical cases and their geographical location.

TBE is a growing concern in Europe, but the surveillance and notification schemes are not uniform and not always mandatory and may affect the prevalence estimates for the disease in certain regions [25,26]. Main problems are the lack of a Europe-wide standard case definition, wide differences in the quality of national surveillance of TBE cases, and varying diagnostic procedures. Thus, surveillance data from different countries are difficult to compare. Furthermore, little is known about the true TBE virus prevalence in tick populations or about the circulation of new subtypes in Europe.

Currently, the European Network for Diagnostics of “Imported” Viral Diseases (ENIVD) is finalising a project to improve the diagnostic and monitoring of encephalitis viruses in Europe. Its tasks are being defined in several working groups [27]. Here, the ENIVD-working group for TBE virus describes the results of a questionnaire survey on the present TBE surveillance situation in Europe, which will help to develop recommendations for the standardisation and quality control in TBE surveillance and diagnostics.


To request information on TBE surveillance and prevention activities in national surveillance systems, a questionnaire with 10 questions was mailed to contact points in all member states of the European Union (EU) and three non-EU countries (Norway, Russia and Switzerland) based on an ENIVD database of expert microbiologists and epidemiologists. The questions were the following:

  1. Is TBE a notifiable disease in your country? (Since when?)
  2. Is there an official reference base to which the annual number of cases is reported?
  3. Does a clear case definition for TBE exist? (If yes, what is it?)
  4. What kind of diagnostic assays are used most often to diagnose TBE?
  5. Is there an expert or reference laboratory for TBE infections in your country? (If yes, what are their contact details?)
  6. What was the annual number of human cases between 2004 and 2007?
  7. Are there any regular investigations regarding tick-transmitted diseases? (If yes, what kind of investigations?)
  8. Do you map endemic foci/risk areas? (If yes, based on what kind of data?)
  9. Is there an official vaccination programme for TBE in your country?
  10. Are there official recommendations regarding TBE vaccination for travellers to TBE endemic areas?


Of 30 contacted countries, 19 EU member states and three non-EU countries (Norway, Russia and Switzerland) participated in this survey (recovery rate: 73%) (Figure 1). All contributors are listed in the acknowledgements section. The completed questionnaires were returned during the summer trimester of 2007. The TBE case numbers for 2007 were added afterwards in February/March 2008. Therefore, the results of this survey reflect national surveillance systems and case numbers for TBE up to these dates.

Case reporting

While TBE cases were specifically notifiable in 16 of the 22 participating countries (73%), at the time of the survey, notification of TBE was not mandatory in Belgium, France, Italy, Portugal, Spain and the Netherlands (Figure 1). Of the 16 countries with TBE notification, eight (Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovenia and Sweden) had a case definition based on clinical criteria and laboratory confirmation, two (Estonia and Finland) also included cases with an epidemiological link (e.g. tick bite), and the remaining six countries (Latvia, Lithuania, Norway, Russia, Slovakia, and Switzerland) had no officially or clearly formulated case definition (Table 1). From Finland and Sweden we know, that the present case definitions are under discussion and will soon be harmonised among the Baltic and Nordic states (the discussion started in October 2007 and is planned to be done by June 2008).

Although clear case definitions were provided by ten countries, differences could be seen in the classification of relevant TBE cases as aseptic meningitis, meningoencephalitis and/or meningoencephalomyelitis (see e.g. classifications in Austria, Czech Republic, Hungary or Slovenia), as well as in the application of laboratory tests for case confirmation (Table 1). Commonly, the routine laboratory diagnosis of TBE is based on the detection of specific antibodies by enzyme linked immunosorbent assay (ELISA) as done in 20 participating countries (91%). Polymerase chain reaction (PCR) is included for particular investigations (e.g. tick studies or severe cases) by 10 countries (45%); followed by other methods like immunofluorescence assay in five countries; haemagglutination assay and virus neutralisation tests in four countries, respectively; and virus isolation in three countries. Other less common methods like complement fixation test, sequencing and Western blot are used in the Czech Republic and Estonia.

Surveillance activities

While for Italy, Sweden and Switzerland information on further investigations regarding tick-transmitted diseases (e.g. TBE, borreliosis, babesiosis, ehrlichiosis, rickettsiosis) were not available, the other 19 countries could provide these data (Table 1). They conduct mainly human serosurvey studies on borreliosis or TBE (10 countries each), followed by surveys on rickettsiosis in five countries. Surveys on the prevalence of TBE virus in tick populations were also performed in seven countries; for anaplasma (the causative agent of ehrlichiosis in Europe) and borrelia in four countries, and for babesia, rickettsia and other relevant pathogens in three countries, respectively. All countries except Portugal, Slovakia and Spain provided information on what kind of data they based their TBE risk assessments on (Table 1). The mapping of risk areas is mainly based on the geographical incidence of autochthonous clinical cases (18 countries), while seven countries also included data on infected ticks in the risk assessment, and only four countries used data from natural reservoirs (e.g. rodents) or indicator hosts (e.g. roe deer, dogs). The Netherlands used this kind of data only for risk assessment of borreliosis.

Trends in TBE incidence

Based on the data from this survey we are able to present an overview of the TBE situation in 14 European countries from 2004 until 2007 (Figure 2). Other participating countries have provided no (Belgium, Greece, Italy, Portugal, Spain) or only few data (France, The Netherlands, Norway).


For the presented period of the past four years certain tendencies/changes in the TBE incidence can be extracted. Following clear increases of the annual case numbers in 2004-2006 (approximately two-fold) in the Czech Republic (with more than 1,000 cases in 2006, the highest reported number since notification began), Germany (with an all-time high of 546 cases in 2006), Slovenia (with 373 cases in 2006, the highest number since 1994) and Switzerland (with the highest number, 244 cases, in 2006) the incidences in these countries declined in 2007. A similar trend in annual TBE case numbers could be observed for Austria. However, the incidence in Slovenia changed dramatically from 10.2 cases per 100,000 inhabitants in 2004 to 18.6 cases per 100,000 in 2006, and is now similar to incidences in Lithuania and Estonia, countries that are usually among the countries with the highest incidence rates. In Latvia, the incidence has decreased significantly in 2005 and since remained stable with approximately seven cases per 100,000 inhabitants. Among the Nordic countries, Sweden had the highest incidences with a gradual increase from 127 cases in 2005 to 189 cases in 2007. While Lithuania, Poland and Slovakia showed considerable fluctuations in the annual TBE case numbers, the trends in the remaining countries were more or less stable. However, we found high incidence levels in the Czech Republic, Estonia, Latvia, Lithuania and Slovenia in 2007 (5.3-13.2), considerable incidence levels for Slovakia, Sweden, Russia and Switzerland (1.0-2.2), and incidence levels under 1.0 cases per 100,000 inhabitants for Austria, Finland, Germany, Hungary and Poland. The epidemiological and laboratory sources of information for the TBE surveillance data are listed in Table 2.

Vaccination policy

Only in Austria, Finland, Germany, Hungary, Latvia, Slovenia, Russia and Switzerland, TBE vaccination is included in an official governmental vaccination programme under certain conditions. In the remaining 14 countries, it is available as an optional vaccination, partly recommended, but not reimbursed by health insurance companies (Table 1). In Austria (with a successful vaccination campaign since 1981), Germany and Switzerland, health insurance companies cover the vaccination costs for people who are at risk of exposure to ticks in risk areas [28-30]. In Finland, TBE vaccination has been offered for free since 2006 only for the Ǻland islands which have the highest incidence rate of the country. Hungary has a programme only for people at occupational risk. Also in Slovenia, vaccination is only obligatory for forest workers, farmers, military personnel and other occupationally exposed people. In Latvia, a free vaccination programme was started for children from regions with high incidences in March 2007. TBE vaccination in Russia is recommended, but currently not financed by federal budget. There are some programmes on regional level based on province budget or other financial sources.

Travel recommendations

Austria, Belgium, Estonia, Finland, Germany, Greece, Latvia, Lithuania, Poland, Slovakia, Slovenia, Spain and Switzerland stated that they had more or less official recommendations regarding TBE vaccination for people travelling to endemic areas, the other nine participating countries did not provide information on this issue (Table 1). Although the responses to this part of the questionnaire suggested that the contact points had not interpreted the question in the same way, it can be deduced that information for travellers is given for following purposes:

a) General information included in national vaccination programmes for citizens coming from non-endemic regions (e.g. in Austria and Poland);
b) Information on the endemic status of a country for citizens and visitors (limited information in the Baltic states, Slovakia and Slovenia, and comprehensive information in Finland, Germany and Switzerland);
c) Information on the endemic status of foreign countries for citizens travelling abroad (e.g. in Belgium and Spain).


TBE is an emerging disease which occurs and spreads among central and western European countries, Scandinavia, countries from the former Soviet Union, and Asia where it has a significant impact on public health. The epidemiology of TBE is very complex, and closely related to the distribution of ixodid ticks. Based on this survey which comprises updated information on TBE surveillance in Europe since the last overview published in 2004 [31], TBE is a notifiable disease, namely in Austria, the Baltic states, Czech Republic, Finland, Germany, Greece, Hungary, Norway, Poland, Russia, Slovakia, Slovenia, Sweden and Switzerland.

While we were able to present an overview of the TBE situation in 14 European countries (based on annual case numbers from 2004 to 2007) in which the disease poses a major threat to public health, other participating countries provided no or only very few data for this survey. A reason for this could be that TBE is not indigenous or a disease of minor importance in these countries. However, single cases of TBE have been documented in France in the Alsace region and more recently in Bordeaux [32], in the northern as well as central part of Italy [1], in northern Greece [33], and also in Norway (southern coast area) and Denmark (Bornholm) [34]. Unfortunately, details about the TBE annual case numbers in Romania and other eastern European countries could not be obtained and remain unclear.

To understand the described tendencies and changes in the TBE incidence during the past four-year-period as well as the fluctuation in incidence rates observed particularly during the last decade among European countries, a complex interrelation of several factors has to be considered, such as social, ecological and/or technological factors [15, 17-24]. It seems more appropriate to base a discussion of the TBE epidemiology on these factors – the importance of which can vary depending on the country – rather than on climate change alone. In particular, due to the mild winter in 2006/2007, it was not to be expected that the TBE incidences would decline in 2007 for Austria, the Czech Republic, Germany, Slovenia and Switzerland. Similar observations have been discussed in previous publications regarding the increase of incidence and appearance of new foci, for example in Nordic and Baltic states [24,35]. Thus changes of leisure activities in nature, increasing/decreasing mobility to risk areas, changes in wildlife hosts/tick populations, improved diagnostics or vaccination campaigns may have influenced the quantity and quality of epidemiological data. In the case of Latvia, the observed decrease in incidence from approximately 11 cases per 100,000 inhabitants in 2004 to seven cases per 100,000 in 2005 and the following years, probably reflects the initiation of vaccination activities [36].

Knowledge about endemic foci needs to be expanded (also in countries where TBE is of minor importance) and regularly updated in order to identify the risk for the exposed population and to apply TBE vaccines in an optimal way. For an appropriate collection of epidemiological data, a broad standard case definition including all possible clinical signs of laboratory-confirmed TBE should be used in European countries in order to avoid under-ascertainment of cases and to increase the knowledge on the true incidence of TBE [25,26].

Currently, the routine laboratory diagnosis of TBE is based mainly on the detection of specific antibodies in serum and CSF, usually by ELISA. However, certain limitations need to be taken into consideration when using serological methods [37]: An early diagnosis by detecting only IgM is questionable, since IgM antibodies can persist for up to 10 months in vaccinees or individuals who acquired the infection naturally. Therefore, confirmation by detection of specific IgG is recommended, but may turn out negative in the first phase of infection. Although it is necessary to monitor IgG titres one or two weeks later for a possible increase, this is rarely done. Moreover, a major problem when using ELISA and IFA are cross-reactions of antibodies induced by other flavivirus infections or vaccinations (e.g. Dengue virus, West Nile virus, Yellow fever virus and Japanese encephalitis virus). It is therefore advised to verify positive results by neutralisation test. Due to the use of infectious virus particles, this requires the handling in biosafety level 3 facilities, making the test time-consuming, expensive and only available in highly specialised laboratories. PCR techniques have also been developed in a remarkable way lately and new publications reveal that RT-PCR methods can be of great diagnostic value in the early diagnosis of TBE and in the discrimination among virus subtypes [37]. However, they are mainly restricted to the first phase of infection. Serological and/or molecular testing should be performed using standard operation protocols (SOPs) among European countries and should be regularly monitored by external quality assurance programmes to guarantee the comparability of data from clinical diagnosis, epidemiological surveillance and surveys on the incidence of TBE virus in ticks and vertebrate hosts [38].

While Lyme borreliosis, another tick-transmitted disease of similar epidemiological importance in Europe, can be treated with antibiotics, no specific treatment for TBE is available to date and the administration of TBE immunoglobulin for a passive post-exposure prophylaxis is highly questionable [39] and not recommended anymore for example in Germany. The last application was discontinued many years ago as the preparations for passive immunisation are no longer produced.

Due to the fact that TBE causes high costs for health care systems (intensive care in hospitals, possible long-lasting cognitive and neuropsychiatric sequelae etc.) TBE vaccination should be recommended and reimbursed for residents of and travellers to TBE endemic areas, who are at risk of tick bites. The Austrian example shows that systematically increased vaccination coverage will result in the decrease of morbidity and therefore hospitalised cases [16]. A further important question of great public health impact, not addressed in this survey, is the diagnosis of vaccine failure [25]. The protective efficacy of the widely used TBE vaccines cannot be properly evaluated if no quality assurance exists for the diagnosis of vaccine failures. Since this is a difficult procedure, the question arises of whether national reference laboratories on CNS diseases should handle the relevant tests and establish widely accepted criteria on how to define a vaccine failure. Furthermore, since awareness among tourists as well as consulting doctors is rather rare [22] recommendations for travellers should be provided by state institutions regardless of whether these institutions are in countries with endemic (e.g. Germany) or non-endemic (e.g. Spain) situation. These can be done using country-specific risk profiles based on the epidemiological data. Today, existing risk maps on this issue are mainly distributed through the vaccine manufacturers. Bringing national data on incidences and prevalence together and distributing such maps may therefore be an important role for a European public health institution.

The participating countries mainly applied the surveillance data from clinical cases as an indicator for predicting endemic foci and for recommending preventive measures. Due to the fact that incidences of human cases may decrease in future because of mass vaccination programmes, alternative indicators for risk assessment are necessary. Therefore, the intro-duction of tick or animal reservoir surveys for prevalence studies of TBE virus have a high priority and should be implemented in national surveillance systems as initiated in previous studies [40-42] . So far, methods for measuring virus prevalence in ticks or animal reservoirs have not been standardised, and reliable tools should be introduced to translate epizootic prevalence data into infection risk for humans.

The implementation of the recommendations given in this report could be helpful, to gain more valuable clinical and epidemiological data on TBE, to improve national surveillance systems and to reduce the incidence rate for the most important flavivirus CNS infection in Europe.

*On behalf of the Working Group for Tick-borne encephalitis virus in the European Network for Diagnostics of “Imported” Viral Diseases (ENIVD)


The ENIVD is partially funded by the European Commission’s Directorate-General for Health and Consumer Protection (DG SANCO) under the programme AIDS and other communicable diseases Grant No. 2004206. We are indebted for information regarding the national surveillance system on TBE to: Stephan Aberle, Medical University of Vienna, Austria; Paul Heyman, RLVBD Queen Astrid Military Hospital, Brussels, Belgium; Marjan van Esbroeck, Institute of Tropical Medicine Antwerp, Belgium; Hana Zelená, Institute of Public Health Ostrava, Czech Republic; Kuulo Kutsar, Health Protection Inspectorate, Tallinn, Estonia; Olli Vapalahti, Haartman Institute, Helsinki, Finland; Hervé Zeller, UBIVE Institut Pasteur, Lyon, France; Sandra Essbauer, Martin Pfeffer & Gerhard Dobler, Bundeswehr Institute of Microbiology, Munich, Germany; Anna Papa, Aristotle University of Thessaloniki, Greece; Ildikó Visontai, National Center for Epidemiology, Budapest, Hungary; Antonino Di Caro, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani", Rome, Italy; Tatjana Kolupajeva, Infectiology Center of Latvia, Riga, Latvia; Algirdas Griskevicius, Lithuania AIDS Center, Vilnius, Lithuania; Gabriel Anestad, Norwegian Institute of Public Health, Oslo, Norway; Wlodzimierz Gut, National Institute of Health, Warsaw, Poland; Maria J. Alves, CEVDI National Institute of Health, Lisboa, Portugal; Alexander Platonov, Central Research Institute of Epidemiology, Moscow, Russia; Milan Labuda (*22.03.1945 – †31.08.2007), Slovak Academy of Sciences, Bratislava, Slovakia; Margareta Sláciková & Viera Jančulová, Health Authority of the Slovak Republic, Bratislava, Slovakia; Tatjana Avšič-Županc, University of Ljubljana, Slovenia; Antonio Tenorio, CNM Instituto de Salud Carlos III, Majadahonda-Madrid, Spain; Sirkka Vene & Malin Arneborn, Swedish Institute for Infectious Disease Control, Solna, Sweden; Detlev Schultze, Institut für Klinische Mikrobiologie und Immunologie, St. Gallen, Switzerland; Gert-Jan Godeke, Rijksinstituut vor Volksgezondheid, Bilthoven, The Netherlands; Gerard van Doornum, Erasmus MC, Rotterdam, The Netherlands.

  1. Pugliese A, Beltramo T, Torre D. Emerging and re-emerging viral infections in Europe. Cell Biochem Funct. 2007;25(1):1-13.
  2. Günther G, Haglund M. Tick-borne encephalopathies: epidemiology, diagnosis, treatment and prevention. CNS Drugs. 2005;19(12):1009-32.
  3. Charrel RN, Attoui H, Butenko AM, Clegg JC, Deubel V, Frolova TV, et al. Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect. 2004;10(12):1040-55.
  4. Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Res. 2003;57(1-2):129-46.
  5. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine. 2003;21(Suppl 1):S36-40.
  6. Kunze U, Baumhackl U, Bretschneider R, Chmelik V, Grubeck-Loebenstein B, Haglund M, et al. The Golden Agers and Tick-borne encephalitis. Conference report and position paper of the International Scientific Working Group on Tick-borne encephalitis. Wiener Med Wochenschr. 2005;155(11-12):289-94.
  7. Kaiser R. Tick-borne encephalitis (TBE) in Germany and clinical course of the disease. Int J Med Microbiol. 2002;291(Suppl 33):58-61.
  8. Mickiene A, Laiskonis A, Günther G, Vene S, Lundkvist A, Lindquist L. Tickborne encephalitis in an area of high endemicity in Lithuania: disease severity and long-term prognosis. Clin Infect Dis. 2002;35(6):650-8.
  9. Randolph S. Tick ecology: processes and patterns behind the epidemiological risk posed by ixodid ticks as vectors. Parasitology. 2004;129(Suppl):S37-65.
  10. Süss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine. 2003;21(Suppl 1):S1-35.
  11. Labuda M, Kozuch O, Zuffová E, Elecková E, Hails RS, Nuttall PA. Tick-borne encephalitis virus transmission between ticks cofeeding on specific immune natural rodent hosts. Virology. 1997;235(1):138-43.
  12. Jääskeläinen AE, Tikkakoski T, Uzcàtegui NY, Alekseev AN, Vaheri A, Vapalahti O. Siberian subtype tick borne encephalitis virus, Finland. Emerg Infect Dis. 2006;12(10):1568-71.
  13. Golovljova I, Vene S, Sjölander KB, Vasilenko V, Plyusnin A, Lundkvist A. Characterization of tick-borne encephalitis virus from Estonia. J Med Virol. 2004;74(4):580-8.
  14. Süss J, Schrader C, Abel U, Bormane A, Duks A, Kalnina V. Characterization of tick-borne encephalitis (TBE) foci in Germany and Latvia (1997-2000). Int J Med Microbiol. 2002;291(Suppl 33):34-42.
  15. Korenberg EI, Kovalevskii YV. Main features of tick-borne encephalitis eco-epidemiology in Russia. Zenralbl Bakteriol. 1999;289(5-7):525-39.
  16. Kunz C. TBE vaccination and the Austrian experience. Vaccine. 2003;21(Suppl 1):S50-5.
  17. Kerbo N, Donchenko I, Kutsar K, Vasilenko V. Tickborne encephalitis epidemiology in Estonia, 1950-2004. Euro Surveill. 2005;10(6):E050630.7. Available from:
  18. Zimmermann H. Tickborne encephalitis in Switzerland: significant increase in notified cases, 2005. Euro Surveill. 2005;10(10):E051006.3. Available from:
  19. Haglund M. Occurrence of TBE in areas previously considered being non-endemic: Scandinavian data generate an international study by the International Scientific Working Group for TBE (ISW-TBE). Int J Med Microbiol. 2002;291 (Suppl 33):50-4.
  20. Randolph S. The changing incidence of tickborne encephalitis in Europe. Eurosurveillance Weekly [1812-075X]. 2002;6(23) 020606. Available from:  
  21. Randolph S. Predicting the risk of tick-borne diseases. Int J Med Microbiol. 2002;291(Suppl 33):6-10.
  22. Bröker M, Gniel D. New foci of tick-borne encephalitis virus in Europe: consequences for travellers from abroad. Travel Med Infect Dis. 2003;1(3):181-4.
  23. Kunze U. Tick-borne encephalitis: from epidemiology to vaccination recommendations in 2007. New issues – best practices. Wien Med Wochenschr. 2007;157(9-10):228-32.
  24. Sumilo D, Bormane A, Asokliene L, Vasilenko V, Golovljova I, Avsic-Zupanc T, et al. Socio-economic factors in the differential upsurge of tick-borne encephalitis in central and Eastern Europe. Rev Med Virol. 2008;18(2):81-95.
  25. Günther G, Lindquist L. Surveillance of tick-borne encephalitis in Europe and case definition. Euro Surveill. 2005;10(1):2-3. Available from:
  26. Stefanoff P, Eidson M, Morse D, Zielinski A. Evaluation of tickborne encephalitis case classification in Poland. Euro Surveill. 2005;10(1):23-5. Available from:
  27. Donoso Mantke O, Vaheri A, Ambrose H, Koopmans M, de Ory F, Zeller H, et al. Analysis of the surveillance situation for viral encephalitis and meningitis in Europe. Euro Surveill. 2008;13(3). Available from:
  28. Bundesministerium für Gesundheit, Familie und Jugend. Austrian vaccination plan 2007. Available from:
  29. Robert-Koch-Institut. Recommendations on TBE vaccination from the Standing Committee on Vaccination (STIKO) in Germany. Available from: Infekt/Impfen/STIKO__Empfehlungen/STIKO__Weitere/FSME/15__ 07,templateId=raw,property=publicationFile.pdf/15_07.pdf
  30. Bundesamt fuer Gesundheit. Recommendations on TBE vaccination in Switzerland from the Federal Office of Public Health, Section Vaccinations. Bull BAG 2006; Nr. 13: 225-31.
  31. Tickborne encephalitis in Europe: basic information, country by country. Eurosurveillance Weekly [1812-075X]. 2004;7(29) 040715. Available from:
  32. Herpe B, Schuffenecker I, Pillot J, Malvy D, Clouzeau B, Bui N, et al. Tickborne encephalitis, southwestern France. Emerg Infect Dis. 2007;13(7):1114-6.
  33. Pavlidou V, Geroy S, Diza E, Antoniadis A, Papa A. Epidemiological study of tick-borne encephalitis virus in Northern Greece. Vector-Borne Zoonotic Dis. 2007;7(4):611-5.
  34. Skarpaas T, Golovljova I, Vene S, Ljøstad U, Sjursen H, Plyusnin A, et al. Tickborne encephalitis virus, Norway and Denmark. Emerg Infect Dis. 2006;12(7):1136-8.
  35. Randolph S. Evidence that climate change has caused ‘emergence’ of tick-borne diseases in Europe? Int J Med Microbiol. 2004;293(Suppl 37):5-15.
  36. Sumilo D, Bormane A, Asokliene L, Lucenko I, Vasilenko V, Randolph S. Tick-borne encephalitis in the Baltic States: identifying risk factors in space and time. Int J Med Microbiol. 2006;296(Suppl 40):76-9.
  37. Donoso Mantke O, Achazi K, Niedrig M. Serological versus PCR methods for the detection of tick-borne encephalitis virus infections in humans. Future Virol. 2007;2(6):565-72.
  38. Donoso Mantke O, Aberle SW, Avšič-Županc T, Labuda M, Ferenczi E, Rozentale B, et al. External quality assurance studies for the serological and PCR diagnostics of tick-borne encephalitis virus infections. Int J Med Microbiol 2008; in press.
  39. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98. Brain. 1999;122(Pt 11):2067-78.
  40. Süss J, Schrader C, Falk U, Wohanka N. Tick-borne encephalitis (TBE) in Germany – epidemiological data, development of risk areas and virus prevalence in field-collected ticks and ticks removed from humans. Int J Med Microbiol. 2004;293(Suppl 37):69-79.
  41. Bormane A, Lucenko I, Duks A, Mavtchoutko V, Ranka R, Salmina K, et al. Vectors of tick-borne diseases and epidemiological situation in Latvia in 1993-2002. Int J Med Microbiol. 2004;293(Suppl 37):36-47.
  42. Labuda M, Elecková E, Licková M, Sabó A. Tick-borne encephalitis virus foci in Slovakia. Int J Med Microbiol. 2002;291(Suppl 33):43-7.

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.